A sponsor that builds its own clinical trial cost estimate before CRO proposals arrive reads those proposals with far more clarity. An independent estimate, built from your protocol assumptions and realistic benchmarks, shows you which bids are missing scope, which assumptions differ from yours, and which prices sit well outside a reasonable range. It also gives your board and investors a budget grounded in your study rather than in whichever proposal happened to arrive first.
What is an independent cost estimate?
It is the sponsor's own view of what the study should cost, organized the way CRO budgets are organized: by service, by unit, and by assumption. Government contracting has long used the same idea, often called an independent government cost estimate, to judge proposals against an internal benchmark. For an emerging biotech, the estimate does not need to be perfect. It needs to be explicit about its assumptions, so that differences from each bid become questions rather than surprises.
What should the estimate include?
Start with the assumptions that drive everything else: number of countries and sites, participants to enroll, expected screen failure rate, enrollment rate per site per month, treatment and follow-up duration, and the number of monitoring visits. Then build out the cost categories:
CRO services by function, such as project management, monitoring, data management, biostatistics, medical monitoring, safety, and regulatory submissions
Investigator grants and site startup fees
Pass-through costs, including ethics review, central laboratory, imaging, courier, and travel
Specialty vendors you may contract directly
Sponsor-side costs such as drug supply, insurance, and internal or fractional staff
Contingency, expressed as a percentage with a stated rationale
Where do the numbers come from?
From several sources, each with a different level of confidence. Your own team's previous studies, published benchmarks, site budget conversations, independent advisors, and earlier proposals all contribute. Record where each number came from and how confident you are in it. A range with a known source is more useful than a precise figure nobody can explain.
How should you use the estimate when bids arrive?
Compare each proposal to your estimate by function and by unit, in addition to the total. A bid that lands close to your total may still be light on monitoring and heavy on project management. Investigate any category that differs from your estimate by more than roughly 20 to 25 percent, and ask the CRO to explain the assumption behind it. Sometimes the CRO knows something you did not, such as slower startup in a particular country. Sometimes the proposal assumes a smaller scope than your study requires.
Should you share your estimate with the CROs?
Keep the dollar figures internal and share the assumptions. When every CRO prices the same number of sites, visits, participants, and months, proposals become comparable, and the differences that remain reflect real choices about staffing, approach, and price. Sharing a target total invites proposals that converge on the number instead of on the work.
How accurate does the estimate need to be?
Accurate enough to start good conversations. An estimate within roughly 20 percent of a well-scoped bid is doing its job. The value lies less in the final figure than in the discipline of writing every assumption down before anyone else proposes one for you.
When should you update the estimate?
Revisit it at three points: when the protocol synopsis changes materially, after the bid defense meetings, and once the contract is final. Each update should note what changed and why. By the time of award, the estimate becomes the baseline your finance team uses to track the study, and its assumptions become the yardstick for evaluating change orders later. A sponsor that can say exactly which assumption moved, and by how much, negotiates change orders from a position of clarity.
Keep reading: How CRO Budgets Are Structured and Where They Drift
